Subtype
Malignant Hepatobiliary Neoplasm
CI-CAN-00001136Explore in graph →
1,159 active trials17 approved drugs42 evidence items
- NCIt
- C8609
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001136Explore in graph →
Clinical trials
5,025 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (560)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT04684862 | Infusion System for Hepatic Cancer | active not recruiting | N/A | 100 | Ronald DeMatteo, M.D.OTHER | 1 | Dec 15, 2025 | clinicaltrials |
| NCT03755791 | Study of Cabozantinib in Combination With Atezolizumab Versus Sorafenib in Participants With Advanced Hepatocellular Carcinoma (HCC) Who Have Not Received Previous Systemic Anticancer Therapy(COSMIC-312) | active not recruiting | Phase 3 | 837 | ExelixisINDUSTRY | 34 | Dec 11, 2025 |
| clinicaltrials |
| NCT05320692 | A Study of TACE Combined With Camrelizumab Plus Rivoceranib (Apatinib) in Patients With Incurable Hepatocellular Carcinoma | active not recruiting | Phase 3 | 423 | Jiangsu HengRui Medicine Co., Ltd.INDUSTRY | 1 | Dec 11, 2025 | clinicaltrials |
| NCT07278102 | A Prospective Observational Study on Efficacy of TARE for Early Stage HCC(KURE-YTT-HCC) | active not recruiting | — | 200 | Seoul National University HospitalOTHER | 1 | Dec 11, 2025 | clinicaltrials |
| NCT04238637 | Immunotherapy Combined With Y-90 SIRT Therapy in Advanced Stage Intrahepatic Biliary Tract Cancer (BTC) | active not recruiting | Phase 2 | 50 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05120271 | BOXR1030 T Cells in Subjects With Advanced GPC3-Positive Solid Tumors(DUET-1) | active not recruiting | Phase 1 / Phase 2 | 7 | Sotio Biotech Inc.INDUSTRY | 2 | Dec 5, 2025 | clinicaltrials |
| NCT05174650 | Treatment of Atezolizumab and Derazantinib in Patients With Advanced iCCA With FGFR2 Fusions/Rearrangements | active not recruiting | Phase 2 | 27 | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus NordwestOTHER | 1 | Dec 5, 2025 | clinicaltrials |
| NCT05921552 | Senior Adult Hepatobiliary Prehab Study | active not recruiting | N/A | 25 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Dec 4, 2025 | clinicaltrials |
| NCT02869217 | Study of TBI-1301 (NY-ESO-1 Specific TCR Gene Transduced Autologous T Lymphocytes) in Patients With Solid Tumors | active not recruiting | Phase 1 | 22 | University Health Network, TorontoOTHER | 1 | Dec 3, 2025 | clinicaltrials |
| NCT03983954 | Naptumomab Estafenatox in Combination With Durvalumab in Subjects With Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer. | active not recruiting | Phase 1 | 120 | NeoTX Therapeutics Ltd.INDUSTRY | 2 | Nov 28, 2025 | clinicaltrials |
| NCT03618381 | EGFR806 CAR T Cell Immunotherapy for Recurrent/Refractory Solid Tumors in Children and Young Adults | active not recruiting | Phase 1 | 44 | Seattle Children's HospitalOTHER | 1 | Nov 20, 2025 | clinicaltrials |
| NCT04572633 | The HistoSonics System for Treatment of Primary and Metastatic Liver Tumors Using Histotripsy(#HOPE4LIVER US) | active not recruiting | N/A | 47 | HistoSonics, Inc.INDUSTRY | 1 | Nov 19, 2025 | clinicaltrials |
| NCT06141564 | Detect and Expunge Concealed Tumors of the Liver(DTECT-Liver) | active not recruiting | — | 360 | Johns Hopkins UniversityOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT07233759 | The Study Collect Clinical Data From the Treatment of Liver Cancer With New Drugs After 2019 and Integrate Biochemical and Pathological Indicators to Analyze Prognostic Outcomes, Including Overall Survival, Progression-free Survival, and Complications. | active not recruiting | — | 2,500 | National Taiwan University HospitalOTHER | 1 | Nov 18, 2025 | clinicaltrials |
| NCT01796145 | Fibroscan Study in HCC | active not recruiting | N/A | 207 | Chinese University of Hong KongOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT07230080 | Sequential TACE-SBRT Combined With Targeted Immunotherapy for Patients With Intermediate to Advanced Liver Cancer | active not recruiting | — | 17 | Nanfang Hospital, Southern Medical UniversityOTHER | 1 | Nov 17, 2025 | clinicaltrials |
| NCT06521567 | A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer | active not recruiting | Phase 1 / Phase 2 | 83 | GlaxoSmithKlineINDUSTRY | 6 | Nov 12, 2025 | clinicaltrials |
| NCT05064553 | ALTUS: Performance of a Multi- Target Hepatocellular Carcinoma (HCC) Test in Subjects With Increased Risk | active not recruiting | — | 2,990 | Exact Sciences CorporationINDUSTRY | 1 | Oct 15, 2025 | clinicaltrials |
| NCT07214363 | The Safety and Efficacy of Irreversible Electroporation for the Treatment of Perivascular Liver Cancers | active not recruiting | N/A | 20 | National Taiwan University HospitalOTHER | 1 | Oct 9, 2025 | clinicaltrials |
| NCT07207343 | Symptomatic Abdominal Tumors Are Unsuitable for Surgical Resection, High-intensity Focused Ultrasound (HIFU) Treatment Will be Applied to the Tumors. Postoperatively, Continuous Evaluation and Analysis of the Ablation Effect Will be Performed Using CT or MRI Imaging. | active not recruiting | N/A | 38 | National Taiwan University HospitalOTHER | 1 | Oct 3, 2025 | clinicaltrials |
| NCT07204327 | Atezolizumab Plus Bevacizumab Combined With Locoregional Therapies in Unresectable Hepatocellular Carcinoma (ISMIO-001)(ISMIO001) | active not recruiting | — | 1,136 | Zhongda HospitalOTHER | 1 | Oct 2, 2025 | clinicaltrials |
| NCT04857684 | SBRT + Atezolizumab + Bevacizumab in Resectable HCC | active not recruiting | Early Phase 1 | 20 | Massachusetts General HospitalOTHER | 1 | Oct 1, 2025 | clinicaltrials |
| NCT04756648 | Phase I Clinical Trial of CT0180 Cells in the Treatment of Hepatocellular Carcinoma | active not recruiting | Phase 1 | 21 | Zhejiang UniversityOTHER | 1 | Sep 29, 2025 | clinicaltrials |
| NCT05097911 | Phase I Study of RNA Oligonucleotide, MTL-CEBPA, Atezolizumab and Bevacizumab in Patients With Advanced Hepatocellular Carcinoma. | active not recruiting | Phase 1 | 33 | National University Hospital, SingaporeOTHER | 1 | Sep 23, 2025 | clinicaltrials |
| NCT02628067 | Study of Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-3475-158/KEYNOTE-158) | active not recruiting | Phase 2 | 1,609 | Merck Sharp & Dohme LLCINDUSTRY | 0 | Sep 22, 2025 | clinicaltrials |
| NCT02932956 | Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP)(GAP) | active not recruiting | Phase 1 | 10 | Baylor College of MedicineOTHER | 1 | Sep 19, 2025 | clinicaltrials |
| NCT06205706 | BI-1910 as a Single Agent and in Combination With Pembrolizumab for the Treatment of Advanced Solid Tumors | active not recruiting | Phase 1 / Phase 2 | 35 | BioInvent International ABINDUSTRY | 4 | Sep 19, 2025 | clinicaltrials |
| NCT04669496 | Phase II-III Clinical Trial of PD1 Antibody (Toripalimab), Lenvatinib and GEMOX Neoadjuvant Treatment for Resectable Intrahepatic Cholangiocarcinoma With High-risk Recurrence Factors | active not recruiting | Phase 2 / Phase 3 | 178 | Shanghai Zhongshan HospitalOTHER | 1 | Sep 4, 2025 | clinicaltrials |
| NCT03907852 | Phase 1/2 Trial of Gavo-cel (TC-210) in Patients With Advanced Mesothelin-Expressing Cancer | active not recruiting | Phase 1 / Phase 2 | 57 | TCR2 TherapeuticsINDUSTRY | 2 | Aug 27, 2025 | clinicaltrials |
| NCT06728358 | The Future Management of Patients With Neoplasms of the Gastro-intestinal Tract(SOCRATE) | active not recruiting | N/A | 300 | Fondazione Policlinico Universitario Agostino Gemelli IRCCSOTHER | 1 | Aug 26, 2025 | clinicaltrials |
| NCT03170960 | Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors | active not recruiting | Phase 1 | 914 | ExelixisINDUSTRY | 9 | Aug 17, 2025 | clinicaltrials |
| NCT05613621 | Dissection of the Molecular and Immunological Interaction in Patients With HCC of Viral and Non-viral Etiologies(T4222) | active not recruiting | — | 579 | National Health Research Institutes, TaiwanOTHER | 1 | Aug 15, 2025 | clinicaltrials |
| NCT05822752 | Study to Evaluate Adverse Events, and Change in Disease Activity, When Intravenously (IV) Infused With Livmoniplimab in Combination With IV Infused Budigalimab in Adult Participants With Hepatocellular Carcinoma (HCC)(LIVIGNO-1) | active not recruiting | Phase 2 | 130 | AbbVieINDUSTRY | 7 | Aug 14, 2025 | clinicaltrials |
| NCT05057013 | A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours | active not recruiting | Phase 1 / Phase 2 | 81 | Cancer Research UKOTHER | 1 | Aug 11, 2025 | clinicaltrials |
| NCT04186234 | SBRT for Liver Cancer Before Liver Transplantation | active not recruiting | N/A | 71 | The University of Hong KongOTHER | 1 | Jul 29, 2025 | clinicaltrials |
| NCT03704480 | Durvalumab + Tremelimumab ± Paclitaxel in Advanced BTC After Platinum Chemotherapy.(IMMUNO-BIL) | active not recruiting | Phase 2 | 106 | GERCOR - Multidisciplinary Oncology Cooperative GroupOTHER | 1 | Jul 23, 2025 | clinicaltrials |
| NCT06248528 | Comparing the Prognosis of Patients With HCC and PVTT Treated With Surgery Versus Locoregional Therapy. | active not recruiting | N/A | 1,076 | Chen XiaopingOTHER | 1 | Jul 16, 2025 | clinicaltrials |
| NCT06842563 | Hepatocellular Carcinoma 3 Gene Methylation Combination Detection Kit (PCR Fluorescent Probe Method) Multicenter Clinical Trial | active not recruiting | — | 900 | Singlera Genomics Inc.INDUSTRY | 1 | Jul 9, 2025 | clinicaltrials |
| NCT07048665 | Effectiveness of Trans-Arterial Chemo Embolization for Hepatocellular Carcinoma on Follow-Up CT Triphasic Liver | active not recruiting | — | 60 | Superior UniversityOTHER | 1 | Jul 2, 2025 | clinicaltrials |
| NCT02632305 | A Study to See the Effects That a New Combination of the Three Drugs, Nab-paclitaxel, Gemcitabine, and Cisplatin Has on Biliary Tract Cancer(AX-CSARC) | active not recruiting | Phase 2 | 45 | AHS Cancer Control AlbertaOTHER | 1 | Jun 26, 2025 | clinicaltrials |
| NCT06312826 | Abbreviated MRI Using Gadoxetic Acid Versus Ultrasonography for Surveillance of Early-stage HCC in Patients at High Risk | active not recruiting | N/A | 806 | Asan Medical CenterOTHER | 1 | May 31, 2025 | clinicaltrials |
| NCT04791735 | Value of the Laparoscopic Approach in the Surgical Management of Resectable Hepatocellular Carcinoma(LapCHC) | active not recruiting | N/A | 252 | Assistance Publique - Hôpitaux de ParisOTHER | 1 | May 28, 2025 | clinicaltrials |
| NCT04941287 | Testing A New Combination of Anti-cancer Immune Therapies, Atezolizumab and CDX-1127 (Varlilumab) With or Without the Addition of a Third Anti-cancer Drug, Cobimetinib, for Advanced-Stage Biliary Tract Cancer | active not recruiting | Phase 2 | 57 | National Cancer Institute (NCI)NIH | 1 | May 23, 2025 | clinicaltrials |
| NCT06975917 | Adjuvant Chemotherapy Regimens in Resected Biliary Tract Cancers (TOG/GI-SAFRADJU-2501)(TOG-SAFRADJU) | active not recruiting | — | 600 | Ankara UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT05657249 | Alternative Surveillance Program for Patients With High Risk Group of HCC | active not recruiting | N/A | 199 | Seoul National University HospitalOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT06966986 | Radiofrequency-responsive Layered Double Hydroxides for Enhanced Arterial Embolization and Thermal Immunotherapy in Hepatocellular Carcinoma | active not recruiting | — | 130 | The Fourth Affiliated Hospital of Zhejiang University School of MedicineOTHER | 1 | May 13, 2025 | clinicaltrials |
| NCT04521153 | Camrelizumab Combined With Apatinib Mesylate for Perioperative Treatment of Resectable Hepatocellular Carcinoma | active not recruiting | Phase 2 / Phase 3 | 294 | Shanghai Zhongshan HospitalOTHER | 1 | May 11, 2025 | clinicaltrials |
| NCT05179824 | Tempus Priority Study: A Pan-tumor Observational Study | active not recruiting | — | 1,000 | Tempus AIINDUSTRY | 1 | May 6, 2025 | clinicaltrials |
| NCT05128123 | Influence of Social Determinants of Health on the Management of HCC in the French National Cohort Study CHIEF(SOCIAL-CHIEF) | active not recruiting | — | 1,600 | University Hospital, GrenobleOTHER | 1 | Apr 20, 2025 | clinicaltrials |
Data updated 23 days agoSource updated Dec 15, 2025source: clinicaltrials